Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837594 | 0.91 | NR3C1 (0.51) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL838520 | 0.91 | NR3C1 (0.48) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL838181 | 0.89 | NR3C1 (0.47) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL839293 | 0.89 | NR3C1 (0.48) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL837360 | 0.89 | NR3C1 (0.43) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL838615 | 0.86 | NR3C1 (0.43) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL836933 | 0.81 | CCR1 (0.39) | NR3C1 | |
| SCHEMBL4277385 | 0.78 | NR3C1 (0.72) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL4277680 | 0.75 | NR3C1 (0.68) | NR3C1CYP11B2CYP11B1 | |
| SCHEMBL4278356 | 0.75 | NR3C1 (0.84) | NR3C1CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | claimed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | claimed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | claimed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | claimed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | claimed |
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | disclosed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | disclosed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | NR3C1 1/4885CYP11B2 28/4885CYP11B1 25/4885 |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | NR3C1 1/4885CYP11B2 28/4885CYP11B1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.